phrykt

Clover Health Investments, Corp. /De (CLOV): who owns it and who trades it

As of Nov 16, 2026, CLOV insiders reported 41 open-market sales worth $8.7M and no purchases in the last 12 months, with 88% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew Toy (CEO), with $4M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Clover Health Investments

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CLOV

225 funds and institutions reported CLOV shares worth $789M at the end of Q2 2026. The largest holder is BlackRock, Inc. with $184M.

10 largest owners, by value

BlackRock, Inc.$184M
Vanguard Capital Management LLC$94.5M
Geode Capital Management, LLC$56.8M
State Street Corp$53.3M
Nuveen, LLC$33M
Charles Schwab Investment Management Inc$28.9M
Sixth Street Partners Management Company, L.P.$28.9M
Vanguard Portfolio Management LLC$23.4M
Northern Trust Corp$19.8M
PNC Financial Services Group, Inc.$18.7M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.35.11M–$184M+10%
Vanguard Capital Management LLC18.04M–$94.5M+6%
Geode Capital Management, LLC10.85M–$56.8M+8%
State Street Corp10.18M–$53.3M+6%
Nuveen, LLC6.29M–$33M+573%
Charles Schwab Investment Management Inc5.52M–$28.9M+4%
Sixth Street Partners Management Company, L.P.5.52M–$28.9M–
Vanguard Portfolio Management LLC4.47M–$23.4M+21%
Northern Trust Corp3.77M–$19.8M+14%
PNC Financial Services Group, Inc.3.56M–$18.7M-5%
Dimensional Fund Advisors LP3.15M–$16.5M-8%
Vanguard Fiduciary Trust Co2.92M–$15.3M+4%
Renaissance Technologies LLC2.81M–$14.7M-17%
Morgan Stanley2.29M–$12M+5%
Citadel Advisors LLC2.16M–$11.3M+15%
D. E. Shaw & Co., Inc.1.97M–$10.3M+2060%
Marshall Wace, LLP1.56M–$8.2M–
Invesco Ltd.1.34M–$7M+30%
GMT Capital Corp1.31M–$6.8MNo change
Mackenzie Financial Corp1.30M–$6.8M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CLOV insiders reported $0 of open-market purchases and $8.7M of sales. 88% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$8.7M
41 trades, 8 people
Sales under a 10b5-1 plan
88%
Share of sale value
Latest trade
Oct 20, 2026
Filed Oct 20, 2026

Purchases and sales by month

$2.5M$2.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 20, 2026Karen SoaresChief Legal OfficerSale plan19,275$4.66$89.8KForm 4
Oct 19, 2026Jamie L. ReynosoCEOSale plan4,066$4.41$17.9KForm 4
Oct 15, 2026Jamie L. ReynosoCEOSale plan18,273$4.68$85.5KForm 4
Oct 15, 2026Conrad WaiCEOSale plan23,627$4.68$111KForm 4
Oct 15, 2026Joseph Clay ThorntonCFOSale plan4,591$4.68$21.5KForm 4
Oct 15, 2026Karen SoaresChief Legal OfficerSale plan14,673$4.68$68.7KForm 4
Oct 15, 2026Andrew ToyCEOSale plan62,176$4.68$291KForm 4
Oct 7, 2026Jamie L. ReynosoCEOSale plan2,006$4.63$9.3KForm 4
Oct 5, 2026Jamie L. ReynosoCEOSale plan8,750$4.42$38.7KForm 4
Oct 1, 2026Andrew ToyCEOSale plan318,806$4.19$1.3MForm 4
Sep 17, 2026Jamie L. ReynosoCEOSale plan1,921$4.56$8.8KForm 4
Sep 16, 2026Joseph Frank OldakowskiVice presidentSale plan3,170$4.64$14.7KForm 4
Sep 15, 2026Conrad WaiCEOSale plan300,000$4.72$1.4MForm 4
Sep 15, 2026Karen SoaresChief Legal OfficerSale plan6,846$4.78$32.7KForm 4
Sep 15, 2026Jamie L. ReynosoCEOSale plan9,273$4.78$44.3KForm 4
Sep 14, 2026Joseph Frank OldakowskiVice presidentSale20,000$5.16$103KForm 4
Aug 17, 2026Joseph Clay ThorntonCFOSale plan17,775$4.39$78KForm 4
Aug 10, 2026Andrew ToyCEOSale plan87,798$4.65$408KForm 4
Jul 20, 2026Karen SoaresChief Legal OfficerSale plan51,700$4.51$233KForm 4
Jul 17, 2026Jamie L. ReynosoCEOSale plan4,839$4.53$21.9KForm 4
Jul 15, 2026Andrew ToyCEOSale plan62,711$4.67$293KForm 4
Jul 15, 2026Conrad WaiCEOSale plan24,215$4.67$113KForm 4
Jul 15, 2026Jamie L. ReynosoCEOSale plan13,119$4.67$61.3KForm 4
Jul 15, 2026Karen SoaresChief Legal OfficerSale plan10,519$4.67$49.1KForm 4
Jul 15, 2026Joseph Clay ThorntonCFOSale plan4,630$4.67$21.6KForm 4
Jul 8, 2026Jamie L. ReynosoCEOSale plan2,384$4.68$11.2KForm 4
Jul 6, 2026Jamie L. ReynosoCEOSale plan6,229$5.26$32.8KForm 4
Jul 1, 2026Andrew ToyCEOSale plan313,476$5.32$1.7MForm 4
Jun 17, 2026Jamie L. ReynosoCEOSale plan2,360$4.78$11.3KForm 4
Jun 16, 2026Joseph Frank OldakowskiVice presidentSale plan12,102$4.86$58.8KForm 4
Jun 15, 2026Karen SoaresChief Legal OfficerSale plan4,681$4.61$21.6KForm 4
Jun 15, 2026Jamie L. ReynosoCEOSale plan6,350$4.61$29.3KForm 4
Jun 11, 2026Jamie L. ReynosoCEOSale plan7,289$4.91$35.8KForm 4
May 28, 2026Conrad WaiCEOSale plan220,426$3.99$879KForm 4
May 18, 2026Carladenise Armbrister EdwardsDirectorSale67,160$3.42$230KForm 4
May 13, 2026Brady Patrick PriestCEOSale98,039$3.52$345KForm 4
Mar 18, 2026Jamie L. ReynosoCEOSale plan5,833$1.91$11.1KForm 4
Mar 4, 2026Brady Patrick PriestCEOSale175,000$2.17$380KForm 4
Jan 20, 2026Jamie L. ReynosoCEOSale plan4,597$2.58$11.9KForm 4
Jan 7, 2026Jamie L. ReynosoCEOSale plan2,102$2.53$5.3KForm 4
Dec 18, 2025Jamie L. ReynosoCEOSale plan4,913$2.61$12.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Andrew ToyChief Executive Officer, Director–$4MOct 15, 2026
Conrad WaiCEO, Counterpart Health–$2.5MOct 15, 2026
Brady Patrick PriestCEO of Home Care–$725KMay 13, 2026
Karen SoaresChief Legal Officer–$495KOct 20, 2026
Jamie L. ReynosoCEO, Medicare Advantage–$449KOct 19, 2026
Carladenise Armbrister EdwardsDirector–$230KMay 18, 2026
Joseph Frank OldakowskiVP OF FINANCE AND CONTROLLER–$177KSep 16, 2026
Joseph Clay ThorntonInterim CFO–$121KOct 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CLOV short interest

23.03M CLOV shares are sold short. Over the last 12 reports the number of shares short went down 38%.

As of Oct 30, 2026, 23.03M CLOV shares were sold short, down 11.3% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 6.7 trading days (days to cover).

Shares short

23.03MMay 15Oct 3039.67M

Days to cover

6.7May 15Oct 307.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202623.03M–-11%3.42M6.7
Oct 15, 202625.95M–+13%4.86M5.3
Sep 30, 202622.90M–-2%3.63M6.3
Sep 15, 202623.45M–-1%4.53M5.2
Aug 31, 202623.68M–-9%3.45M6.9
Aug 14, 202626.14M–-7%5.25M5.0
Jul 31, 202628.24M–-2%3.93M7.2
Jul 15, 202628.75M–+30%5.88M4.9
Jun 30, 202622.18M–-11%7.92M2.8
Jun 15, 202624.85M–-13%9.96M2.5
May 29, 202628.60M–-24%8.25M3.5
May 15, 202637.39M–-4%8.13M4.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Clover Health Investments company events

Clover Health Investments filed 19 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026LeadershipThe Board of Directors of the Company appointed Joseph Clay Thornton, age 37, the Company’s Interim Chief Financial Officer and principal financial officer, to serve as the Company’s Chief Financial Officer on a permanent basis, and appointed Joseph Frank Oldakowski, age 44, the Company’s Vice… Filing
  2. Oct 9, 2026AnnouncementShared information with investors. Filing
  3. Sep 25, 2026LeadershipAmended an earlier report. The Board of Directors of Clover Health Investments, Corp. appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board. Filing
  4. Sep 24, 2026LeadershipThe Board of Directors of Clover Health Investments, Corp. appointed Senator Robert G. Torricelli to serve as a Class I director of the Board and Dr. Brian J. Miller, M.D., M.B.A., M.P.H. to serve as a Class III director of the Board. Filing
  5. Aug 20, 2026AnnouncementShared information with investors. Filing
  6. Aug 5, 2026ResultsReleased financial results. Filing
  7. Jul 17, 2026AnnouncementClover Health Investments, Corp. became aware of anomalous login activity on certain of its information systems. Filing
  8. Jun 18, 2026AnnouncementAs previously disclosed, on June 9, 2026, the Centers for Medicare & Medicaid Services informed Clover Health Investments, Corp. that, consistent with a court judgment in Clover Insurance Co. V. HHS, Civ. Filing
  9. Jun 16, 2026LeadershipBrady Priest notified Clover Health Investments, Corp. of his decision to step down from his position as Chief Executive Officer of Clover Care Services, the Company’s home-care business, effective as of July 3, 2026. Filing
  10. Jun 12, 2026VoteReported shareholder vote results. Filing
  11. Jun 10, 2026AnnouncementThe United States District Court for the Southern District of Georgia entered final judgment in Clover Insurance Co. v. Filing
  12. May 18, 2026AnnouncementShared information with investors. Filing
  13. May 6, 2026ResultsReleased financial results. Filing
  14. Apr 1, 2026LeadershipThe board of directors of Clover Health Investments, Corp. approved a transition of the Chief Financial Officer role. Filing
  15. Mar 6, 2026AnnouncementAmended an earlier report. Shared information with investors. Filing
  16. Mar 6, 2026AnnouncementShared information with investors. Filing
  17. Feb 26, 2026ResultsReleased financial results. Filing
  18. Jan 14, 2026AnnouncementShared information with investors. Filing
  19. Dec 10, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Clover Health Investments financials

Famous investors that hold CLOV

4 of the 50 well-known investors we track reported holding CLOV in their latest 13F filing. The largest position is Jim Simons's, worth $19.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20264.55M$19.6M0.0%+62%
Ken Griffin · Citadel AdvisorsQ3 20262.82M$12.1M0.0%+30%
Steve Cohen · Point72 Asset ManagementQ3 20262.15M$9.3M0.0%+101%
Israel Englander · Millennium ManagementQ3 2026231,382$997K0.0%-79%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Clover Health Investments, Corp. /De (CLOV) stock

Who owns the most CLOV stock?

The largest reported owner of Clover Health Investments, Corp. /De (CLOV) is BlackRock, Inc.. In total, 225 funds and institutions reported holding CLOV at the end of Q2 2026. See the largest owners.

Are CLOV insiders buying or selling?

In the last 12 months, CLOV insiders reported no open-market purchases and 41 sales worth $8.7M. The latest trade was on Oct 20, 2026. See every trade.

What is the short interest in CLOV?

As of Oct 30, 2026, 23.03M CLOV shares were sold short, down 11.3% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 6.7 trading days (days to cover). See the history.

Which famous investors hold CLOV?

4 of the 50 well-known investors we track reported CLOV in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $19.6M. See all holders.

Executive pay

Clover Health Investments's chief executive was paid a total of $1.3M for the year ended Dec 31, 2025, down 86% from $9.5M the year before. In the last 12 months, Clover Health Investments's executives and directors bought no stock on the open market and sold $8.7M.

Chief executive, total pay$1.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$1.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.